Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. (TARS) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · TARS · as of Sep 30, 2025
Ownership Breakdown
225
Institutional Holders
▲ 18 vs Q2
$2.67B
Total Inst. Value
▲ $798.96M vs Q2
43.02M
Shares Outstanding
freeFloat 93.82%
44.89M
13F Shares Held
▼ 1.24M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
TARS largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. biological products, (no diagnostic substances) | 3.78M | 8.92% | 8.92% | $224.62B | Nov 12, 2025 | ▼ 12.6K |
RTW INVESTMENTS, LP biological products, (no diagnostic substances) | 3.18M | 7.50% | 7.50% | $188.84B | Nov 14, 2025 | ▲ 65.8K |
DEEP TRACK CAPITAL, LP biological products, (no diagnostic substances) | 3.00M | 7.08% | 7.08% | $178.29B | Nov 14, 2025 | ▲ 1.25M |
PARADIGM BIOCAPITAL ADVISORS LP biological products, (no diagnostic substances) | 2.67M | 6.29% | 6.29% | $158.42B | Nov 14, 2025 | ▼ 310.4K |
JENNISON ASSOCIATES LLC biological products, (no diagnostic substances) | 2.60M | 6.15% | 6.15% | $154.79B | Oct 30, 2025 | ▲ 136.6K |
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 2.45M | 5.79% | 5.79% | $145.89B | Nov 14, 2025 | — held |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 2.27M | 5.36% | 5.36% | $135.03B | Nov 7, 2025 | ▼ 25.3K |
MORGAN STANLEY biological products, (no diagnostic substances) | 1.91M | 4.51% | 4.51% | $113.65B | May 27, 2026 | ▼ 143.3K |
JANUS HENDERSON GROUP PLC biological products, (no diagnostic substances) | 1.44M | 3.40% | 3.40% | $85.55B | Nov 14, 2025 | ▼ 367.9K |
ASSENAGON ASSET MANAGEMENT S.A. biological products, (no diagnostic substances) | 1.25M | 2.95% | 2.95% | $74.17B | Oct 7, 2025 | ▲ 250.4K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
21
Increased
+2.65M shares4
New Positions
first time holders20
Decreased
−2.17M shares0
Sold Out
fully exitedNet shares change (top 50)
+482.2K
+2.65M / −2.17M
Net new holders
+5
4 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
TARS insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
23
Buy transactions
52
Sell transactions
0.44
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Neervannan Seshadri Chief Operating Officer | Mar 20, 2026 | Sale | 2,989 | $66.75 | $199.5K | 82.8K | Form 4 ↗ |
Whitfield Dianne C. Chief Human Resources Officer | Mar 17, 2026 | Sale | 4,029 | $69.42 | $279.7K | 43.3K | Form 4 ↗ |
Whitfield Dianne C. Chief Human Resources Officer | Mar 18, 2026 | Sale | 4,071 | $68.71 | $279.7K | 39.2K | Form 4 ↗ |
Whitfield Dianne C. Chief Human Resources Officer | Mar 19, 2026 | Sale | 4,174 | $67.00 | $279.7K | 35.0K | Form 4 ↗ |
Wahl Bryan General Counsel | Mar 17, 2026 | Sale | 4,084 | $69.42 | $283.5K | 72.3K | Form 4 ↗ |
Wahl Bryan General Counsel | Mar 18, 2026 | Sale | 4,125 | $68.71 | $283.4K | 68.2K | Form 4 ↗ |
Wahl Bryan General Counsel | Mar 19, 2026 | Sale | 4,231 | $67.00 | $283.5K | 64.0K | Form 4 ↗ |
Neervannan Seshadri Chief Operating Officer | Mar 17, 2026 | Sale | 3,125 | $69.42 | $216.9K | 94.0K | Form 4 ↗ |
Neervannan Seshadri Chief Operating Officer | Mar 18, 2026 | Sale | 3,610 | $68.71 | $248.0K | 90.4K | Form 4 ↗ |
Neervannan Seshadri Chief Operating Officer | Mar 19, 2026 | Sale | 4,589 | $67.00 | $307.5K | 85.8K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Tarsus Pharmaceuticals, Inc. (TARS) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 6.18%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Tarsus Pharmaceuticals, Inc. is BLACKROCK, INC., holding approximately 3.78 million shares — equal to 8.92% of outstanding shares — as of September 30, 2025.
A total of 225 institutional investors currently hold TARS stock, with a combined institutional value of approximately $2.67 billion as of the most recent 13F filing period.
Frequently asked questions
TARS ownershipTarsus Pharmaceuticals, Inc. (TARS) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is BLACKROCK, INC. with a 8.92% stake. Company insiders hold 6.18%. Data sourced from SEC Form 13F as of September 30, 2025.